Rheumatic adverse effects with biologics targeting type 2 inflammation in severe asthma: a VigiBase study

Affiliations

• ¹ Department of Respiratory Medicine, Faculty of Medicine, Toulouse University Hospital, Toulouse, France.
• ² Department of Medical and Clinical Pharmacology, Faculty of Medicine, Toulouse University Hospital, Toulouse, France; Centre d'Investigation Clinique de Toulouse CIC1436, Inserm, équipe PEPSS "Pharmacologie En Population Cohortes et Biobanques," Toulouse, France.
• ³ Rheumatology Department, Pierre-Paul Riquet Hospital, University-Paul Sabatier Toulouse III, Toulouse, France; Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity) INSERM UMR1291-CNRS UMR5051-Université Toulouse III, CRISALIS F-CRIN, Toulouse, France.
• ⁴ Department of Respiratory Medicine, Faculty of Medicine, Toulouse University Hospital, Toulouse, France; Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity) INSERM UMR1291-CNRS UMR5051-Université Toulouse III, CRISALIS F-CRIN, Toulouse, France. Electronic address: guilleminault.l@chu-toulouse.fr.